Effectiveness of Transarterial Embolization of Hepatocellular Carcinoma as a Bridge to Transplantation

被引:13
|
作者
Hodavance, Michael S. [1 ]
Vikingstad, Eric M. [1 ]
Griffin, Andrew S. [1 ]
Pabon-Ramos, Waleska M. [1 ]
Berg, Carl L. [2 ]
Suhocki, Paul V. [1 ]
Kim, Charles Y. [1 ]
机构
[1] Duke Univ, Med Ctr, Div Vasc & Intervent Radiol, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Div Gastroenterol, Durham, NC 27710 USA
关键词
TRANSCATHETER ARTERIAL EMBOLIZATION; AWAITING LIVER-TRANSPLANTATION; CIRRHOTIC-PATIENTS; FOLLOW-UP; CHEMOEMBOLIZATION; THERAPY; DROPOUT; SURVIVAL; ABLATION; CRITERIA;
D O I
10.1016/j.jvir.2015.08.032
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To assess the effectiveness of bland transarterial embolization of hepatocellular carcinoma (HCC) as a "bridge" to transplantation. Materials and Methods: In this retrospective study, 117 patients with HCC that met Milan criteria underwent bland embolization as their initial and sole therapy for treatment of HCC (88 men and 29 women; mean age, 60.4 y; range, 35-88 y). Subsequent postembolization contrast-enhanced computed tomography or magnetic resonance imaging studies were reviewed to determine whether Milan criteria were met in an intent-to-transplant analysis. Freedom from progression beyond Milan criteria and survival were calculated by Kaplan-Meier technique. Predictors of progression and survival were also assessed. Results: After embolization, 87% and 78% of patients' disease still met Milan criteria at 6 and 12 months, respectively. The median tithe until disease progression beyond Milan criteria was 22.6 months,(95% confidence interval, 16.2-29 mo). alpha-Fetoprotein levels, number of lesions, United Network for Organ Sharing stage, Model for End-stage Liver Disease score, and, cirrhosis etiology did not correlate significantly with stability within Milan criteria. A total of 34 patients (29%) underwent : eventual liver tranSplantation at a median of 3.3 months (range, 00-20.9 mo). Liver transplantation was a significant independent predictor of longer survival (6.9 y vs 2.6 y; P < .001). The major complication rate within 30 days of embolization was 2.6%, including one mortality. Conclusions: Bland transarterial embolization as a bridging strategy to maintain HCC within Milan criteria was suceessful in 78% of patients at 1 year, which compares favorably with other locoregional embolotherapies.
引用
收藏
页码:39 / 45
页数:7
相关论文
共 50 条
  • [1] Significance of transarterial embolization for hepatocellular carcinoma in liver transplantation
    Cheng, YF
    Chen, CL
    Huang, TL
    Tsang, LC
    Sun, PL
    [J]. LIVER TRANSPLANTATION, 2003, 9 (06) : C12 - C12
  • [2] The significance of transarterial embolization for advanced hepatocellular carcinoma in liver transplantation
    Sun, PL
    Chen, CL
    Hsu, SL
    Huang, TL
    Chen, TY
    Chen, YS
    Tsang, LC
    Cheng, YF
    [J]. TRANSPLANTATION PROCEEDINGS, 2004, 36 (08) : 2295 - 2296
  • [3] Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis
    Patel, Mikin V.
    Davies, Heather
    Williams, Abimbola O.
    Bromilow, Tom
    Baker, Hannah
    Mealing, Stuart
    Holmes, Hayden
    Anderson, Nicholas
    Ahmed, Osman
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 1061 - 1071
  • [4] Transarterial embolization of metastatic mediastinal hepatocellular carcinoma
    Chia-Chang Chen
    Hong-Zen Yeh
    Chi-Sen Chang
    ChungWang Ko
    Han-Chung Lien
    Chun-Ying Wu
    Siu-Wan Hung
    [J]. World Journal of Gastroenterology, 2013, (22) : 3512 - 3516
  • [5] Transarterial chemoembolization and bland embolization for hepatocellular carcinoma
    Tsochatzis, Emmanuel A.
    Fatourou, Evangelia
    O'Beirne, James
    Meyer, Tim
    Burroughs, Andrew K.
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (12) : 3069 - 3077
  • [6] Transarterial chemoembolization and bland embolization for hepatocellular carcinoma
    Emmanuel A Tsochatzis
    Evangelia Fatourou
    James O'Beirne
    Tim Meyer
    Andrew K Burroughs
    [J]. World Journal of Gastroenterology, 2014, 20 (12) : 3069 - 3077
  • [7] Transarterial embolization of metastatic mediastinal hepatocellular carcinoma
    Chen, Chia-Chang
    Yeh, Hong-Zen
    Chang, Chi-Sen
    Ko, Chung-Wang
    Lien, Han-Chung
    Wu, Chun-Ying
    Hung, Siu-Wan
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (22) : 3512 - 3516
  • [8] Transarterial Chemoinfusion for Hepatocellular Carcinoma as Downstaging Therapy and a Bridge toward Liver Transplantation
    De Luna, W.
    Sze, D. Y.
    Ahmed, A.
    Ha, B. Y.
    Ayoub, W.
    Keeffe, E. B.
    Cooper, A.
    Esquivel, C.
    Nguyen, M. H.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 (05) : 1158 - 1168
  • [9] The cost-effectiveness of TheraSphere in patients with hepatocellular carcinoma who are eligible for transarterial embolization
    Manas, Derek
    Bell, Jon K.
    Mealing, Stuart
    Davies, Heather
    Baker, Hannah
    Holmes, Hayden
    Hubner, Richard A.
    [J]. EJSO, 2021, 47 (02): : 401 - 408
  • [10] Transarterial Chemoembolization with Epirubicin-eluting Beads versus Transarterial Embolization before Liver Transplantation for Hepatocellular Carcinoma
    Nicolini, Antonio
    Martinetti, Laura
    Crespi, Silvia
    Maggioni, Marco
    Sangiovanni, Angelo
    [J]. JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2010, 21 (03) : 327 - 332